Waive the Five-Month Waiting Period for Social Security Disability Insurance
The ALS Disability Insurance Access Act (S. 578/ H.R. 1407) would eliminate the five-month Social Security Disability Insurance (SSDI) waiting period for people with ALS. Under current law, people with ALS who qualify for SSDI must wait five months before receiving those benefits. Given the nature of the disease, Congress must eliminate this five-month wait.
Expand Access to Home Infusion for Medicare Beneficiaries
Congress should fix the law to allow Medicare beneficiaries with ALS to receive home infusion of IV medications. As the disease progresses, people with ALS face increased mobility challenges, eventually becoming homebound and requiring care at home. Under current law, there is no Medicare coverage of home infusion for ALS drugs. Medicare Part B beneficiaries must leave the home to receive infusions at a hospital, doctor’s office or infusion center; Medicare Part D only covers the IV medication, leaving beneficiaries to pay out-of-pocket for home infusion pharmacy and nursing services. Private insurance fully covers home infusion. The ALS Association is advocating to expand Medicare coverage of home infusion that is equivalent to private coverage.
Fairly Compensate Families of Veterans with ALS
The Justice for ALS Veterans Act (S. 3091/H.R. 4748) would increase dependency and indemnity compensation (DIC) paid to surviving spouses of veterans who die from ALS regardless of how long the veteran had ALS prior to death. Because ALS is a service-connected disease, families of deceased veterans receive a DIC. However, they are denied a supplemental DIC increase available only to families of veterans who live at least eight years with a service-connected disability. Families of veterans who died from ALS deserve the same compensation as other military families. The ALS Association is collaborating with stakeholders across the veterans’ health network to enact this legislation.
Preserve and Increase Federal Resources for ALS Research
- ALS Research Program – Department of Defense:
In fiscal year (FY) 2020, The ALS Association initiated and led the campaign to double funding from $10 to $20 million for the Department of Defense (DOD) ALS Research Program (ALSRP). For FY 2021, Congress should again double funding from $20 to $40 million. Increased funding is needed because ALSRP has only been able to fund half of the most promising research applications it receives. Studies funded by the DOD, VA and NIH have found that people who served in the military are up to twice as likely to develop and die from ALS as those with no history of military service regardless of which branch they served in, where they served, or whether they served during peace or war. The DOD ALSRP program is funded as a part of the Congressional Directed Medical Research Program.
- National ALS Registry/Biorepository – Centers for Disease Control and Prevention:
Congress should provide at least $10 million in FY 2021 to continue the Center for Disease Control and Prevention’s (CDC) National ALS Registry/Biorepository. The Registry collects and analyzes health claims and other data in close collaboration with the DOD, Veteran’s Administration, Medicare and the National Institutes of Health. It connects people living with ALS to researchers conducting clinical trials across the U.S., collects and shares biological samples through the Biorepository and funds its own important risk factor research.
- National Institutes of Health – Department of Health and Human Services:
Congress should provide at least a $44.7 billion in FY 2021 for the National Institutes of Health (NIH), a $3 billion increase over FY 2020, to increase investments in ALS research. NIH spent approximately $83 million on ALS research in 2018, with the National Institute of Neurological Disorders and Stroke (NINDS) making the largest investment, and four other NIH Institutes contributing the balance.
Expand Access to Telehealth
The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act (S. 2741/ H.R. 4932) and Protecting Access to Post-Covid-19 Telehealth Act (H.R. 7663) would expand access to telemedicine and telehealth for people with ALS. The ALS Association will work closely with stakeholders across the health care and technology ecosystem to expand a legal and regulatory environment where providers are permitted to deliver safe, high quality care using telehealth and telemedicine regardless of care delivery location or technological method.
Represent People Living with ALS on Access to Health Care, Drugs and Therapies
The ALS Association is an active participant in coalitions of leading patient advocacy organizations that advocate to ensure protections for preexisting conditions and access to high quality, affordable care in public and private insurance. Efforts include advocating for access to complex rehab technologies like wheelchairs, making permanent access to speech generating devices, and protecting access to ventilators. Additionally, the Association is working with other organizations to advance our Principles for Urgent, Patient-Centered Clinical Trials. Efforts to advance these principles include increasing access to experimental therapies and fast-tracking Food and Drug Administration development and approval of new effective drugs for everyone with ALS, including the Promising Pathway Act (H.R. 7269/ S. 3872) to establish a time-limited, provisional approval pathway for certain drugs and biological products.